Inactive Instrument

Pharmacyclics, Inc. Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE

15-05-06	Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	RE
15-04-29	Mylan NV : Exclusive - Perrigo expected to reject Mylan's latest offer	RE
15-04-21	Mylan NV : Generic drugmaker Teva makes $40 billion offer for rival Mylan	RE
15-04-21	Mylan NV : Exclusive - Perrigo expected to reject Mylan offer as soon as this week	RE
15-04-08	Actavis : Generic drugmaker Mylan offers $29 billion for Perrigo	RE
15-03-05	AbbVie : CEO defends Pharmacyclics deal to sceptical investors	RE
15-03-05	Wall Street closes up slightly ahead of jobs report	RE
15-03-05	AbbVie : CEO says new form of Humira could thwart generics	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
15-03-05	AbbVie : Biotech buys get pharma M&A off to flying start in 2015	RE
15-03-05	AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	RE
14-06-02	Dai ichi Life Insurance : U.S. futures flat with Dow, S&P at record levels	RE

16-01-07	Pharmacyclics : Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma	PU
16-01-07	Pharmacyclics : AbbVie’s Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent	PU
16-01-07	Pharmacyclics : AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment–Naïve Chronic Lymphocytic Leukemia	PU
16-01-07	Pharmacyclics : IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenström’s Macroglobulinemia in Europe	PU

15-03-05	Wall Street se reprend un peu dans un climat d'attente
15-03-05	DJ Industrial : Wall Street se reprend un peu dans un climat d'attente
15-03-05	AbbVie : Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	Début d'année en fanfare pour les fusions dans la pharmacie
15-03-05	AbbVie : Wall Street quasiment stable après les chiffres du chômage

Manager	Title	Age	Since
Scott Reents PRN	Corporate Officer/Principal	59	-
Dana Lee PRN	Corporate Officer/Principal	62	2013-01-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-6.23%	+26.01%	-2.99%	23.36B
Average	+4.55%	-0.42%	+52.31%	+162.82%	42.27B
Weighted average by Cap.	+3.23%	-0.29%	+47.66%	+161.47%

Employees

Sector